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Abstract
Thyroid glands play a critical role in fetal brain development during pregnancy and in the regulation of 
growth and metabolic function after development. Thyroid dysfunction has become a common clinical problem 
nowadays and the incidence is increasing each year. However, the ideal approach for adequate diagnosis 
and management of thyroid dysfunction still becomes a debate among endocrinologists. Several guidelines for 
thyroid dysfunction management have been established by various group of experts, mostly focused on thyroid 
nodules. Subclinical hyperthyroidism (SH) and subclinical hypothyroidism is considered as a laboratory than a 
clinical diagnosis. In order to achieve compliance with accepted protocols, an appropriate interpretive reports 
should be an integral part of the investigation of both SH and subclinical hypothyroidism. The medications 
of anthytiroid drugs, radioactive iodine, and surgery are considered as treatments for SH. Whereas oral 
levothyroxine treatment is chosen as a therapy for subclinical hypothyroidism. Taken together, diagnosis and 
management of both SH and hypothyroidism need regular monitoring of thyroid function. Even though expert 
panels already released various guidelines for the diagnosis and management of thyroid dysfunction, each 
patient should be assessed individually to determine the most suitable treatment. Until adequate data are 
available, clinical judgment was combined with patient’s preferences to improve best practice.
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Disfungsi Tiroid Subklinis: Diagnosis dan Tatalaksana
Abstrak
Kelenjar tiroid berperan penting dalam perkembangan otak janin selama masa kehamilan dan regulasi 
pertumbuhan serta fungsi metabolisme pada masa pertumbuhan. Dewasa ini, gangguan tiroid menjadi 
masalah kesehatan di masyarakat seiring meningkatnya kasus tiroid setiap tahunnya, namun diagnosis dan 
manajemen penanganan penyakit gangguan tiroid masih menjadi perdebatan di kalangan ahli  endokrin. 
Pedoman manajemen program pengendalian penyakit tiroid telah ditetapkan oleh kelompok ahli dengan fokus 
kepada masalah nodul tiroid. Hipertiroidisme subklinis (HS) dan hipotiroidisme subklinis lebih dikenal sebagai 
diagnosis laboratorium daripada diagnosis klinis. Untuk mencapai kesesuaian dengan protokol yang berlaku, 
maka suatu interpretasi yang tepat merupakan bagian yang penting dari evaluasi HS dan hipotiroidisme 
subklinis. Terapi dengan obat antitiroid, pemberian yodium radioaktif, atau  operasi merupakan pilihan terapi 
untuk HS. Sedangkan pengobatan levotiroksin oral merupakan terapi pilihan untuk hipotiroidisme subklinis. 
Dianosis dan tatalaksana HS dan hipotiroidisme subklinis memerlukan pemantauan fungsi tiroid secara 
teratur. Meskipun kesepakatan ahli sudah mengeluarkan berbagai pedoman untuk diagnosis dan tatalaksana 
disfungsi tiroid, setiap pasien tetap harus dinilai secara individual untuk menentukan tatalaksana yang paling 
tepat. Sebelum data terkumpul lengkap diperlukan kombinasi antara penilaian klinis dan pilihan tatalaksana 
oleh pasien untuk memberi hasil yang terbaik.
Kata kunci: hipertiroid subklinis; hipotiroid subklinis; Graves’ disease.
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Introduction
Thyroid glands play a critical role in fetal brain 
development during pregnancy and in the regulation 
of growth and metabolic function after development. 
Thyroid dysfunction has become a common clinical 
problem nowadays but the incidence is increasing 
each year. At  present the concept of subclinical 
thyroid disease is common and its management 
remains debatable. To update proper diagnosis and 
management of subclinical thyroid dysfunction, the 
American Association of Clinical Endocrinologist 
(AACE) and American Thyroid Association (ATA) 
joined together to hold a consensus development 
conference which aims to compile the clinical 
practice guideline for management of thyroid 
disease. That practice recommendations are 
nowadays used by the clinicians as a guideline for 
thyroid disease examination. 
Subclinical Hyperthyroidism
Subclinical hyperthyroidism (SH) occurs when 
thyroid-stimulating hormone (TSH) serum levels 
are very low and hardly detectable with a normal 
free thyroxine (T4), total triiodothyronine (TT3), and 
free triiodothyronine (FT3) levels. Its prevalence 
is approximately 1% in the population and is 
commonly found in elderly groups. Majority of 
patients suffering from this disease experiences no 
clinical symptoms, thus laboratory evaluation are 
an essential prerequisite for diagnosing SH.1,2 
A review of guidelines by various panel experts 
classifies SH into two categories depending on the 
severity. Patients with Grade 1 mild SH have a low but 
still detectable TSH serum levels (i.e 0.1–0.39 mIU/L), 
whereas patients showing low TSH serum level less 
than 0.1 mIU/L are classified as Grade 2 severe SH. 
The prevalence of SH varies with the TSH level cutoff 
used to define it. European Thyroid Association (ETA) 
use a TSH cutoff of a 0.39 mIU/L as upper limit of 
Grade 1 SH, meanwhile ATA/AACE had developed the 
guidelines that suggested TSH cutoff of a 0.5 mIU/L.1,2
Diagnosis of Subclinical Hyperthyroidism
 Three essential steps are required to 
diagnose SH. (Figure 1)  At first, the diagnosis of 
persistent SH need to be established, initially by 
the screening of TSH serum level. When  serum 
TSH level is low, FT4 and FT3 are measured. 
Once the diagnosis has been set up, the next step 
is to establish the etiology of SH. A radioiodine 
uptake, thyroid ultrasonography and scan, and 
TSH-receptor antibodies examination could be 
performed to determine the etiology to start the 
treatment. Etiology and differential diagnosis of SH 
as seen in Table 1. The last step is to determine the 
risks associated with SH and appropriate treatment1 
Table 1. Etiology and Differential Diagnosis of Subclinical Hyperthyroidism1
Origin Condition
Endogenous •	 Graves’ disease
•	 Toxic adenoma
•	 Multinodular goiter
Exogenous •	 Excessive thyroid hormone replacement therapy
•	 Intentional thyroid hormone suppressive therapy
Causes of transient SH •	 Treatment of overt hyperthyroidism with antithyroid drug or 
radioiodine
•	 Subacute thyroiditis, painless and silent thyroiditis
Causes of low TSH serum 
concentrations that are not 
SH
•	 Pituitary or hypothalamic insufficiency
•	 Psychiatric illness
•	 Drugs that suppress serum TSH (dopamine, high dose 
of glucocorticoids, somatostatin analogues, dobutamine, 
amphetamine, bexarotene, bromocriptine)
•	 Severe non-thyroidal illness (euthyroid sick syndrome)
•	 Late first trimester of pregnancy
•	 Could happen in blacks as a consequence of racial 
differences
•	 Smoking
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Figure 1. Algorithm for Evaluation of Suspected Subclinical Hyperthyroidism3
Complications of Subclinical Hyperthyroidism
Thyroid dysfunction in patient suffering SH 
tends to be stable, however there is possibilities of 
few patient progress to overt hyperthyroid or else 
revert to the euthyroid state. TSH concentration 
suppression can be used as an indication of 
subtle progress to overt hyperthyroidism. The TSH 
levels turn to normal state, occurred in 20–50% of 
patients with Grade 1 SH, thus the progression to 
overt hyperthyroidism is really uncommon. Grade 
2 patients, in contrast, more commonly progress to 
overt hyperthyroidism. Every year, 5-8% of Grade 2 
SH patients may progress to overt hyperthyroidism.1 
Etiology of SH may predict the course of 
progression. However, in case of Graves’ disease 
- an autoimmune disorder associated with 
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hyperthyroidism - it has been complicated to predict 
the developed hyperthyroidism, compared with 
the patient with toxic multinodular goiter. Patients 
with Graves’ disease are more likely to experience 
remission or progression, rather than having 
persistent SH. On the other side, patients with SH 
caused by multinodular goiter, which is commonly 
living in a relatively low iodine intake’s areas, 
tend to have stable thyroid dysfunction. However, 
progression to overt hyperthyroidism frequently 
occurs in Grade 2 SH caused by toxic multinodular 
goiter in iodine-deficiency areas, especially after 
supplementation with iodine or exposure to an 
iodine-containing medication.1
Symptoms of Hyperthyroidism and Quality of 
Life
SH results in a variety of symptoms and signs, 
which are palpitations, tremble, anxiety, heat 
intolerance, excessive sweating, and reduced 
exercise tolerance. All of these conditions can 
decrease a patient’s quality of life, particularly 
in young patient.  Adrenergic symptoms may be 
improved with cardio-selective β-blocker agents or 
antithyroid drugs.1
Dementia or Cognitive Impairment. Thyroid 
hormone is known as a pivotal regulator in fetal 
brain development and have a critical role in 
maintaining biological function after development. 
The evidence on risk of dementia in SH remain 
controversial. Large prospective studies alongside 
with long-term follow-up cases is needed to confirm 
the association between dementia and cognitive 
impairment with SH.1,4,5 
Cardiovascular and Mortality Risk. While 
it is well-known that overt hyperthyroidism have 
a correlation with cardiovascular dysfunction, SH 
effect on the heart is minimally understood. SH 
may induce several cardiovascular effects including 
increased average heart rate, left ventricular mass 
- specifically septal and posterior wall thickness, 
and the greater risk of atrial arrhythmia as well. In 
addition, it also reduces heart rate variability.1 Some 
studies have reported that substitutive therapy 
with L-thyroxine was associated with improved 
echocardiographic parameter and heart maximal 
workload, while other studies proved otherwise.1,6 
Osteoporosis and Fractures. Thyroid 
hormone play a pivotal role in bone development 
and is regarded as the factor to stimulate 
osteoclastic bone resorption. Several reports 
have demonstrated the link between bone 
fracture and osteoporosis in the presence of overt 
hyperthyroidism. The duration and other factors 
determine the likelihood of developing bone loss 
in SH. Adults with Grade 2 SH have a greater risk 
of losing up to 20% of bone mineral density due 
to excessive bone resorption activity led by overt 
hyperthyroidism.7-9  Therefore, Grade 2 SH patients 
who have risk factors for bone loss (e.g elderly and 
postmenopausal) should be further assessed.1
Treatment for Subclinical Hyperthyroidism (SH)
There are some controversial on when to 
treat SH, possibly due to the lack of promising 
intervention studies. Nevertheless, ATA/AACE 
and ETA developed their own guidelines on when 
to consider treatment for SH based on available 
evidences (Figure 2).1 Elderly age >65 years with 
TSH <0.1mU/L should be treated while those who 
have TSH level 0.1-0.5 mU/L is considered for 
having treatment. As for individual age <65 years 
with heart disease and/or osteoporosis and/or 
hyperthyroid symptoms (TSH <0.1 mU/L) need 
to be treated, those with TSH 0.1-0.5 mU/L also 
considering treatment. Adults age <65 years with 
menopause and/or asymptomatic considered for 
treatment regarding their low serum TSH level. 
 Existing treatments for SH includes 
antithyroid drugs, radioactive iodine, and surgery. 
Antithyroid medication available – methimazole - 
should be started on a lower starting dose and the 
side effects should be monitored. Treatment with 
radioactive iodine and surgery should be followed 
with thyroid hormone replacement (levothyroxine).
Recommendations on Biochemical and 
Morphological Diagnosis of Endogenous SH 
1. Initial test for SH diagnosis could be done 
by performing serum TSH measurement. 
Confronted with the low serum TSH level, 
thyroid hormones (FT4 and TT3 or FT3) should 
be examined.
2. TSH assay is carried out to assess the severity 
of SH and to distinguish Grade 1 (serum TSH: 
0.1–0.39 mIU/L) from Grade 2 SH (TSH <0.1 
mIU/L).
3. Causes of transient TSH or subnormal 
TSH serum not associated with SH, such 
as administration of drugs, pituitary or 
hypothalamic insufficiency, psychiatric 
illness, and non-thyroidal illness, should be 
investigated. 
4. Patients with an initial subnormal serum TSH 
with thyroid hormone levels within or at the 
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upper limit of the normal range should be 
retested within 2–3 months because SH is 
interpreted as persistently subnormal TSH 
concentration.
Recommendations on Biochemical and 
Morphological Diagnosis of Endogenous SH 
(Establish Etiology of SH)
1. Scintigraphy and possibly a 24-hour thyroid 
radioactive iodine uptake test could be 
performed in nodular goiter with Grade 2 SH 
to guide clinicians in the choice of treatment.
2. Ultrasonography with color flow doppler can be 
helpful in those who suffering SH and nodular 
goiter.
3. Measurement of TSH-receptor antibody levels 
can confirm the etiology of autoimmune-
induced hyperthyroidism. Furthermore, 
TSH-receptor autoantibodies can identify 
autoimmunity in nodular glands because 
approximately 17% of patients living in iodine-
deficient areas with scintigraphic criteria for 
toxic multinodular goiter may be positive for 
TSH receptor autoantibodies.
Recommendations on Biochemical and 
Morphological Diagnosis of Endogenous SH 
(Establish Appropriate Treatment)
Computed tomography (CT) assessment 
without contrast or magnetic resonance imaging 
is done to evaluate airway compression in patients 
with large multinodular goiter and compressive 
symptoms and signs.
Recommendations on Clinical Evaluation of 
Patients with Endogenous SH Before Treatment
1. Electrocardiography (ECG), holter ECG, and 
doppler echocardiography are recommended 
to assess cardiac rhythm.
2. Bone mineral density and possibly bone turn 
over markers should be checked in selected 
patients with Grade 2 SH patients with risk 
factor for osteoporosis, including elderly and 
postmenopausal women.
Recommendations on Treatment of Endogenous 
SH in Elderly Patients with SH and Low or 
Undetectable TSH
Treatment of SH is recommended in patients 
older than 65 years with Grade 2 SH to avoid the 
risks associated with untreated Grade 2 SH. The 
management of symptomatic and asymptomatic 
treatment for Grade 1 SH patients older than 65 
years – more over those who have metabolic and 
cardiovascular disorders - may be considered to 
avoid the risk of atrial fibrillation. 
Recommendations on Treatment of 
Endogenous SH in Young Patients with SH and 
Low or Undetectable TSH
1. Grade 2 SH patient younger than 65 years 
is suggested to treat in order to improve the 
quality of life and can attenuate the high risk 
of progression of these patients. Symptomatic 
patients can be treated with cardioselective 
β-blocking agents and/or therapies directed 
toward the thyroid dysfunction. The dosage of 
β-blocking agent can be guided by heart rate 
control.
2. Treatment of patients with Grade 2 SH in 
patients with cardiovascular risk factors or 
comorbidities.
3. Treatment in young asymptomatic patients 
with relatively low but detectable TSH is not 
recommended. These patients should be 
monitored without treatment due to low risk 
in overt hyperthyroidism, the possibility of 
spontaneous remission of SH, and the poor 
evidence of adverse health outcomes.
4. Observation is recommended in Grade 1 SH 
patients, lack of ultrasonographic findings of 
thyroid abnormalities, a normal radionuclide 
thyroid scan, normal heart rate on ECG, normal 
BMD, and no cardiovascular or skeletal risks.
5. Serum TSH, free T4, and TT3 or free T3 should 
be evaluated every 6–12 months in untreated 
SH patients with persistent subnormal TSH, 
or as soon as the clinical picture shows any 
changes.
Recommendations on Treatment of Endogenous 
SH According to Etiology
1. Antithyroid medication should be the first 
treatment option in young patient with Grade 
2 SH caused by Graves’ disease and elderly 
patients suffering Grade 1 SH with Graves’ 
disease. Some observations demonstrated 
Graves’ disease has been exemption in 
20-40% patients following 12-18 months 
antithyroid therapy. Radioactive iodine should 
be considered in the condition of antithyroid 
drugs are not tolerated, relapse occur suddenly, 
and in patients with cardiac disease.
2. Antithyroid medication or radioactive iodine 
treatment are recommended for Grade 2 
hyperthyroidism patients with Graves’ disease 
Subclinical Thyroid Dysfunction
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older than 65 years. In some cases, those 
treatments could be applied for patients at high 
risk of adverse cardiac events.
3. Either radioactive iodine therapy or surgery 
should be the preference in SH patients older 
than 65 years due to multinodular goiter or toxic 
adenoma due to their persistent SH. Moreover, 
patients with Grade 2 SH may progress to 
overt hyperthyroidism after excessive iodine 
intake. In cases where radioactive iodine is 
not feasible (e.g. elderly nursing home patients 
suffer from incontinent, patients with severe 
goiter, or those with depression), lifelong low-
dose antithyroid drugs is possible to be given.
4. Surgery is recommended in patients with 
large goiter, symptoms of compression, 
concomitant hyperparathyroidism, or suspicion 
of thyroid malignancy. Total thyroidectomy 
is the treatment of choice in the absence of 
associated conditions or factors, making Grade 
2 SH patients poor candidates for radioactive 
iodine treatment.
Recommendations to Avoid Adverse Effects of 
Treatment of Endogenous SH
1. Low dose of methimazole (5–10 mg/daily) 
should be used to rapidly restore euthyroidism 
in patients with SH. Prior to that, a decent 
information about the potential adverse effects 
of methimazole should be informed to the 
patients. A complete baseline blood count 
and liver profile should be obtained before 
methimazole therapy.
2. The goal of therapy with radioiodine should 
be to obtain a euthyroid state with or without 
levothyroxine treatment.
3. Pretreatment with methimazole before 
radioactive iodine or surgery might be 
considered in patients older than 65 years with 
cardiovascular disease and in patients with 
greater risk of complications due to worsening 
of hyperthyroidism. Although there are no 
data supporting this suggestion, however, 
improvement of radioactive iodine activity 
within 10-15% should be considered after 
pretreatment with antithyroid drugs to maintain 
its efficacy.
4. Patients at high risk of graves’ ophthalmopathy 
progression should be identified before 
radioactive iodine. Steroid prophylaxis is 
recommended in patients with clinically overt 
eye disease and in smokers.
5. According to the American College of 
Cardiology/American Heart Association, the 
first-line treatment of atrial fibrillation and 
heart failure is recommended for patients with 
thyroid dysfunction. Such treatment restored 
euthyroidism in patients since cardiovascular 
drugs are generally unsuccessful while thyroid 
hormone excess persist. Treatment of SH with 
antithyroid drugs should be the first-line therapy 
in elderly with Grade 2 SH and atrial fibrillation 
and/or heart failure to obtain spontaneous 
conversion to sinus rhythm.
6. The American Heart Association suggests 
an anticoagulation with an international 
normalized ratio (INR) of 2.0–3.0, instead of 
thromboembolism, for patients with SH and 
atrial fibrillation. 
7. A periodic follow-up after radioactive iodine 
should be performed during the first year and 
then annually to assess normalization of thyroid 
function or the development of hypothyroidism.
8. Following the radioactive iodine or surgery, 
levothyroxine therapy is given at a replacement 
doses.
9. Either near-total or total thyroidectomy is 
recommended for graves’ disease patients 
to avoid the risk of recurrences after partial 
thyroidectomy. In case of a solitary autonomous 
nodule, lobectomy and isthmus resection is 
sufficient. Total or subtotal thyroidectomy should 
be performed in patients with toxic multinodular 
goiter, with a recurrence rate of <1%.
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Subclinical Hypothyroidism
Subclinical hypothyroidism – or so-called 
mild hypothyroid or preclinical hypothyroidism – is 
characterized by a persistent increased of TSH 
levels despite normal serum level of free T4 and 
T3 in patients with or without any hypothyroid 
symptoms. Its prevalence varies between 4 and 10% 
among population.10 Subclinical hypothyroidism is 
categorized as mildly increased TSH levels (4.0-10.0 
mU/L) and severely increased TSH value (>10 mU/L) 
according to the elevation in the serum TSH level. 
Serum TSH level above 10 mIU/L are 
considered as severe subclinical hypothyroidism 
even in normal level of free T4. Mild subclinical 
hypothyroidism, which account for 90% cases, 
described as elevated TSH level below 10 mIU/L. 
ETA defined normal range of TSH is 0.4–4.4 mIU/L. 
On the other hand, ATA/AACE have different 
reference value, which is 0.5-4.5 mIU/L.10-12 
Measurement of both serum TSH and FT4, along 
with thyroid peroxidase antibodies, should be 
repeated after 2 to 3 months interval to investigate 
the initial raised serum TSH. The measurement is 
done to patients with positive antithyroid peroxidase 
or thyroglobulin antibodies, and to those with a 
hypoechoic or an in homogenous echo pattern on 
thyroid ultrasonography. 
Many cases of SH are left untreated because 
the condition is still considered normal.  However, 
recent studies have shown that subclinical 
hypothyroidism may have harmful effects. Patients 
with subclinical hypothyroidism may progress 
towards overt hypothyroidism, while others 
resolve spontaneously or remain unchanged. In 
consequence, the benefit effects of its diagnosis 
and management remains unclear.10
Multiple factors may lead to the transient increase 
in TSH. Normally, the lowest TSH levels is found in 
the afternoon. TSH reaches its peak concentration, 
approximately 30% higher than afternoon, during 
evening and night. Thus, serial measurements must 
be obtained at the same time of the day to represent 
non-bias TSH baseline. Serum FT4 also need to be 
measured to exclude hypothyroidism.8 Besides its 
circadian fluctuations, TSH levels may vary with age. 
TSH values slightly increased in elderly, especially 
people aged over 80 years old.  It is considered as 
physiology part of aging.10
Table 2. Etiology of Subclinical Hypothyroidism10
Persistent Transient
•	 Autoimmune thyroiditis (Hashimoto’s 
disease)
•	 Germline loss of function mutation in 
TSH receptor
•	 Subacute or painless thyroiditis
•	 Withdrawal of levothyroxine
•	 Various treatment (e.g. lithium 
therapy, amiodarone therapy)
•	 Obesity
•	 Depression
•	 Following vigorous exercise
•	 Irregular sleep pattern
•	 Night shift working
Hashimoto’s disease, an autoimmune 
thyroiditis, is widely known as the most common 
cause of persistent subclinical hypothyroidism 
by increasing antithyroid antibodies. Also, there 
are several causes of transient subclinical 
hypothyroidism (Table 2). Hence, it is important to 
exclude the transient etiologies before performing 
the diagnosis of subclinical hypothyroidism.10 
Autoimmune thyroiditis is the most frequent cause of 
subclinical hypothyroidism, therefore measurement 
of circulating antithyroglobulin antibodies (TgAb) 
and/or antithyroid peroxidase antibodies (TPOAb) 
is needed to confirm the diagnosis of autoimmune 
thyroiditis. The use of ultrasonography may help. 
Hypoechoic or inhomogenous thyroid echo pattern 
may present before circulating autoantibodies.10 
Who need treatment? 
 Only a few of subclinical hypothyroidism 
patients have clinical symptoms, such as dry skin, 
forgetfulness, slower thinking, muscle weakness, 
greater improvement in tiredness, muscle cramps, 
feeling colder, having deeper and hoarser voice, 
and more constipation. Out of all symptoms, a 
study found that the most significant one is extreme 
fatigue and exhaustion. Therefore, subclinical 
hypothyroidism patients with symptoms may get 
benefit from levothyroxine therapy (Figure 3).10
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Mood disturbance/mental health. Patients 
with subclinical hypothyroidism may experience 
memory impairment and mood-swing. Some 
data indicates that the symptoms improved after 
treatment with levothyroxine. However, it may only 
be applied in young patient, not in patients aged 
over 65 years receiving the same drug treatment.10
 Goiter and thyroid cancer. Subclinical 
hypothyroidism is slightly related with goiter, 
especially in children. Increasing TSH levels also 
enhanced the risk of thyroid cancer. However, it is 
still unproven whether levothyroxine therapy may 
decrease the risk of thyroid cancer.10
Obesity. It is well known that hypothyroidism 
may induce obesity. Furthermore, weight gain is 
associated with an increase of TSH levels. However, 
no data available suggested whether levothyroxine 
may improve patients with obesity-related elevation 
of TSH serum levels or not.10
Diabetes Mellitus. The prevalence of thyroid 
dysfunction is about 10% in patient with type 1 
diabetes mellitus (T1DM), meanwhile the number 
of subclinical hypothyroidism and serum thyroid 
autoantibody concentration is as high as 30%. 
In result, TSH levels of T1DM patient should be 
yearly monitored.10  Meanwhile, T2DM may induces 
subclinical hypothyroidism and other thyroid 
problems.13
Dyslipidemia. Subclinical hypothyroidism 
patients with dyslipidemia would benefit from 
levothyroxine therapy. However, lipid profile rarely 
reaches normal with levothyroxine therapy in those 
patients. Even, greater improvement can be seen 
in lipid profile in the condition of pre-treatment 
serum TSH levels >10 mU/L.10,14
Cardiovascular system. Subclinical 
hypothyroidism is associated with changes of 
functional cardiac abnormalities including left 
ventricular diastolic dysfunction and resting 
and exertional systolic function reduction. 
Several reports also shown the correlation of 
hypothyroidism on vascular abnormalities such 
as endothelial dysfunction, arterial stiffness, and 
atherosclerosis. Unfortunately, not enough good 
evidences available on levothyroxine therapy effect 
to cardiovascular profile.10
Younger adults (<65-70 years). A trial of 
levothyroxine replacement therapy to normalize 
serum TSH level should be considered for younger 
patients (<65 years); serum TSH <10 mU/L) 
with symptoms suggestive of hypothyroidism 
even though the evidence for improvement in 
mental function with levothyroxine treatment in 
subclinical hypothyroidism in younger individuals 
is still lacking. In patients with diabetes mellitus, 
different approach should be considered. Serum 
TSH in patients with T1DM should be monitored 
every year. While in patients with type 2 diabetes 
mellitus and an unexplained change in glycemic 
control, serum TSH and FT4 should be measured 
regularly. Levothyroxine therapy of subclinical 
hypothyroidism is able to reduce the level of 
both total and LDL cholesterol, even though 
normalization of serum lipids is rarely achieved. In 
asymptomatic condition, replacement therapy with 
levothyroxine is recommended for younger patients 
with serum TSH >10 mU/L. 
Elderly patient. Subjects aged 80–85 years 
with elevated serum TSH ≤10 mU/L should be 
carefully followed with a wait-and-see strategy to 
avoid hormonal treatment.6,10
Treatment for Subclinical Hypothyroidism
Oral levothyroxine is considered as treatment 
of choice for hypothyroidism, whilst others, i.e. 
liothyronine is not recommended. For patients 
without cardiac disease, a weight-related dose of 
levothyroxine - approximately 1.5 µg/kg/day (e.g. 
75 or 100 µg/day for a woman, 100 or 125 µg/day 
for a man) - should be used. A small starting dose of 
levothyrocine i.e. 25 or 50 µg daily is recommended 
for elderly patients or those with cardiac disease. 
The dose of levothyroxine should be increased by 
25 µg/day every 14–21 days until a full replacement 
dose is reached.6,10
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Figure 3. ETA Algorithm Recommendation on Management of Subclinical Hypothyroidism10
Levothyroxine should be taken on an empty 
stomach. It is recommended to consume this 
drug either in the morning, an hour before 
eating, at bedtime, or 2 hours or more after 
eating. Medications interfering with levothyroxine 
absorption -such as the consumption of calcium 
and iron salts or proton pump inhibitors- should 
be avoided, or taken at least 4 hours following 
levothyroxine ingestion.10
Re-examination of TSH should be done 2 
months following initial levothyroxine therapy 
with the dosage adjustment made accordingly. In 
adults, serum TSH levels should be lower than 
the reference range (0.4–2.5 mU/L). Meanwhile, 
treatments for subclinical hypothyroidism should 
be individualized, gradual, and closely monitored in 
elderly patients. For exceptions, higher treatment 
of TSH within 1–5 mU/L is acceptable for elderly 
patients aged 70-75 years. 10
Treatment should be reviewed 3-4 months 
after a serum TSH reached the reference range 
in patients with mild subclinical hypothyroidism 
(TSH <10 mU/L) who have been started on 
levothyroxine for symptoms attributed to subclinical 
hypothyroidism. In case of levothyroxine causes no 
improvement in symptoms, the treatment need to 
be stopped.  No further examination is required in 
asymptomatic patients in case their thyroid function 
has normalized following an initially abnormal 
serum TSH result.10
In subjects who have subclinical 
hypothyroidism but in whom medication is not 
initiated yet, re-examination of thyroid function 
should be done every 6 months for the first 2 years 
and then yearly thereafter.10
Conclusion
Our review defined that SH and hypothyroidism 
is considered as a laboratory than a clinical 
diagnosis. In order to achieve compliance with 
accepted protocols, an appropriate interpretive 
reports should be an integral part of the 
investigation of both SH and hypothyroidism. The 
medications of anthytiroid drugs, radioactive iodine, 
and surgery are considered as treatments for SH. 
Whereas oral levothyroxine treatment is chosen 
as a therapy for subclinical hypothyroidism. Taken 
together, diagnosis and management of both SH 
and hypothyroidism need regularly monitoring of 
thyroid function. Even though expert panels already 
released various guidelines for the diagnosis and 
management of thyroid dysfunction, each patient 
should be assessed individually to determine the 
most suitable treatment. Until adequate data are 
available, clinical judgment was combined with 
patient’s preferences to improve best practice.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. ETA Algorithm Recommendation on Management of Subclinical 
Hypothyroidism10 
 
Conclusion 
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laboratory than a clinical diagnosis. In order to achieve compliance with 
accepted protocols, an appropriate interpretive reports should be an integral part 
of the investigation of both SH and hypothyroidism. The medications of 
anthytiroid drugs, radioactive iodine, and surgery are considered as treatments 
for SH. Whereas oral levothyroxine treatment is chosen as a therapy for 
subclinical hypothyr idism. T ken together, diagnosis and manag m nt of both 
SH and hypothyroidism need regularly monitoring of thyroid function. Even 
though expert panels already released various guidelines for the diagnosis and 
management of thyroid dysfunction, each patient should be assessed 
individually to determine the most suitable treatment. Until adequate data are 
available, clinical ju gment was combined with patient’s pref renc s to improve 
best practice. 
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